PB2145: IMPACT OF A SIZE OF BONE PLASMACYTOMA ON THE COURSE OF MULTIPLE MYELOMA
E. A. Mamaeva(National Research Center for Hematology Russian Academy of Medical Sciences), Л. П. Менделеева(National Research Center for Hematology Russian Academy of Medical Sciences), Maiia Soloveva(Ministry of Health of the Russian Federation), Ирина Костина, Tatjana Obukhova(National Medical Research Center for Hematology), Maxim Solovev(National Medical Research Center for Hematology)
Cited by 0
Related Papers
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation
|Bone Marrow Transplantation|2014|195
Atlas of RNA sequencing profiles for normal human tissues
|Scientific Data|2019|142
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
|The Oncologist|2010|92
Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma
|Leukemia & lymphoma/Leukemia and lymphoma|2015|59